Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.75 |
| ▸ | MCHR2 | Q969V1 | 6/20 | 0.57 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5862042 | 0.99 | MCHR1 (0.76) | MCHR1MCHR2GLAKDM4ENPC1 | |
| SCHEMBL5862060 | 0.91 | MCHR1 (0.67) | MCHR1MCHR2ALDH1A1 | |
| SCHEMBL5862829 | 0.90 | MCHR1 (0.70) | MCHR1MCHR2KDM4ENPC1RAB9A | |
| SCHEMBL5860851 | 0.87 | MCHR1 (0.61) | MCHR1MCHR2NPC1HTTRAB9A | |
| SCHEMBL5862093 | 0.87 | MCHR1 (0.79) | MCHR1MCHR2 | |
| SCHEMBL5862819 | 0.87 | MCHR1 (0.98) | MCHR1MCHR2GLAMEN1ALDH1A1 | |
| SCHEMBL5862063 | 0.87 | MCHR1 (0.98) | MCHR1MCHR2GLAMEN1ALDH1A1 | |
| SCHEMBL5861327 | 0.86 | MCHR1 (1.00) | MCHR1MCHR2 | |
| SCHEMBL5861296 | 0.85 | MCHR1 (0.60) | MCHR1MCHR2MEN1KMT2A | |
| SCHEMBL5862796 | 0.84 | MCHR1 (0.59) | MCHR1MCHR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049307-B2 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2006-05-23 | — | — | US | claimed |
| US-20050187279-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBVIE INC. | 2005-08-25 | — | — | US | claimed |
| US-20050137187-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | claimed |
| US-7049307-B2 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2006-05-23 | — | — | US | disclosed |
| US-20050187279-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBVIE INC. | 2005-08-25 | — | — | US | disclosed |
| US-20050137187-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137187-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MCHR1 1/4885MCHR2 2/4885GLA 2708/4885 |
| US-20050187279-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MCHR1 1/4885MCHR2 2/4885GLA 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.